Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as it prepares to begin its planned Phase 3 clinical trial of ATH434 for multiple system atrophy.

Tetratherix has exported its first commercial shipment of Tetramatrix polymer to the United States, marking the start of product revenue for the ASX-listed company’s Precision Medicine franchise.

Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a cannabidiol capsule designed to treat insomnia, after an independent review found the study could continue without increasing its planned sample size.

Genetic Signatures and Microba Life Sciences have announced they are in preliminary discussions about a potential merger that would combine rapid infectious disease testing with gut microbiome profiling and create a larger ASX-listed diagnostics business.

Mesoblast reported a sharp rise in revenue as sales of its cell therapy, Ryoncil, accelerated in the United States, while its chronic low back pain program moved closer to a decisive clinical readout.

Neuren Pharmaceuticals has announced it will begin paying dividends to shareholders for the first time, following a sharp increase in royalty income from its Rett syndrome treatment, DAYBUE (trofinetide).

Chief executive Cheryl Maley said the year brought advances in the company’s lead radiopharmaceutical program, new strategic partnerships, and further validation of DEP technology's potential in targeted cancer treatment.

Noxopharm says new laboratory findings strengthen the case for using its Sofra technology to help the immune system recognise cancer cells after treatments such as chemotherapy or radiotherapy kill them.

Entropy Neurodynamics has signed an agreement with the University of California, San Francisco (UCSF), to develop a US Phase 2 trial comparing its intravenous psilocin treatment TRP-8803 with the widely used antidepressant escitalopram in young adults with major depressive disorder.

Chairman Roby Zomer said the development marked the program’s transition from a commercial agreement into formal engagement with the FDA’s veterinary medicines division.

Neuren Pharmaceuticals has reached a major milestone in the global commercialisation of trofinetide after the European Commission granted marketing authorisation for DAYBU to treat neurobehavioural symptoms associated with Rett syndrome.

Genetic Signatures has emerged from a year of restructuring with smaller losses, lower cash burn, and a clearer plan to rebuild growth, despite a decline in revenue amid challenging conditions in its core Australian market.

Nanosonics has entered financial year 2027 with continued growth from its trophon disinfection business, while advancing the commercial rollout of its CORIS endoscope reprocessing platform and commencing a new on-market share buyback of up to $40 million.

Professor Wainwright joins the Queensland medical research institute with a career spanning fundamental biomedical discovery, translational science and senior research leadership across Australia’s medical research sector.

Avecho chief executive Dr Paul Gavin said the timing reflected the program's growing commercial relevance as it approaches a critical clinical and regulatory stage.

Acrux has appointed physician and biopharmaceutical executive Dr Jolanta Airey as its chief medical officer, strengthening its leadership team as it prepares to advance its female testosterone treatment toward Phase 3 clinical trials in the United States.

World-renowned plastic and reconstructive surgeon, Professor Fiona Wood AO, has been announced as the Depaz Orator for the AusBiotech International Conference, held as part of Australia’s Biggest Week in Biotech on the Gold Coast in October 2026.

Telix Pharmaceuticals reported a strong first half of 2026, with double-digit revenue growth and improved margins, supported by continued investment in a late-stage radiopharmaceutical pipeline advancing toward key clinical and regulatory milestones.

Recce Pharmaceuticals has secured Australian ethics approval to expand its pivotal Phase 3 trial of RECCE 327 Topical Gel by adding a head-to-head study against antibiotics currently used to treat diabetic foot infections.

The payment, worth approximately A$14.1 million, is the first instalment under an agreement that gives Everest exclusive rights to develop and commercialise DMX-200 across Greater China, South Korea and selected Southeast Asian markets.

Medical Developments International has reported higher profitability and a sharp improvement in cash generation, with accelerating demand for Penthrox in Australia and Europe supporting a more positive outlook for the emergency pain relief specialist.

Interim chief executive and managing director Gordon Naylor said CSL took decisive action during the year to simplify the organisation, strengthen commercial capabilities, and position newer therapies for growth.

Mesoblast has completed treatment of all 350 patients in its pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain caused by inflammatory degenerative disc disease, putting the company on track for top-line results in mid-2027.

Perth biotechnology company Spartan Therapeutics says it plans to begin a human clinical trial in 2027 of a circular RNA platform designed to restore more youthful function in organs and tissues across the body.